The GPR55 antagonist CID16020046 protects against intestinal inflammation

Neurogastroenterology and Motility

Volumn 27, Issue 10, 2015, Pages 1432-1445

  Stancic A ^a   Jandl, K ^a   Hasenohrl C ^a   Reichmann, F ^a   Marsche, G ^a   Schuligoi, R ^a   Heinemann, A ^a   Storr, M ^b   Schicho, R ^a  

^a MEDICAL UNIVERSITY OF GRAZ   (Austria)

^b LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

DSS; GPR55; Intestinal inflammation; TNBS

Indexed keywords

CD11B ANTIGEN; CID 16020046; CYCLOOXYGENASE 2; DOCUSATE SODIUM; G PROTEIN COUPLED RECEPTOR; G PROTEIN COUPLED RECEPTOR 55; INTERLEUKIN 1BETA; INTERLEUKIN 6; MYELOPEROXIDASE; RECEPTOR BLOCKING AGENT; STAT3 PROTEIN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; 4-(4-(3-HYDROXYPHENYL)-3-(4-METHYLPHENYL)-6-OXO-1H,4H,5H,6H-PYRROLO(3,4-C)PYRAZOL-5-YL)BENZOIC ACID; AZABICYCLO DERIVATIVE; BENZOIC ACID DERIVATIVE; CANNABINOID RECEPTOR; CANNABINOID RECEPTOR ANTAGONIST; DEXTRAN SULFATE; GPR55 PROTEIN, HUMAN; GPR55 PROTEIN, MOUSE; TRINITROBENZENESULFONIC ACID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL MIGRATION; COLITIS; COLON; CONTROLLED STUDY; DISEASE SEVERITY; ENZYME ACTIVITY; FLOW CYTOMETRY; KNOCKOUT MOUSE; LAMINA PROPRIA; LEUKOCYTE; MACROPHAGE; MOUSE; NEUTROPHIL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; ANIMAL; ANTAGONISTS AND INHIBITORS; C57BL MOUSE; CHEMICALLY INDUCED; DRUG EFFECTS; IMMUNOLOGY; MALE;

ANIMALS; AZABICYCLO COMPOUNDS; BENZOATES; CANNABINOID RECEPTOR ANTAGONISTS; COLITIS; DEXTRAN SULFATE; MALE; MICE; MICE, INBRED C57BL; RECEPTORS, CANNABINOID; RECEPTORS, G-PROTEIN-COUPLED; TRINITROBENZENESULFONIC ACID;

EID: 84942296107     PISSN: 13501925     EISSN: 13652982     Source Type: Journal    
DOI: 10.1111/nmo.12639     Document Type: Article

References (57)

1. Ryberg E, Larsson N, Sjögren S, Hjorth S, Hermansson NO, Leonova J, Elebring T, Nilsson K. et al. The orphan receptor GPR55 is a novel cannabinoid receptor. Br J Pharmacol 2007; 152: 1092-101.
2. Oka S, Toshida T, Maruyama K, Nakajima K, Yamashita A, Suigiura T. 2-Arachidonoyl-sn-glycero-3-phosphoinositol: a possible natural ligand for GPR55. J Biochem 2009; 145: 13-20.
3. Ross RA. The enigmatic pharmacology of GPR55. Trends Pharmacol Sci 2009; 30: 156-63.
4. Sharir H, Console-Bram L, Mundy C, Popoff SN, Kapur A, Abood ME. The endocannabinoids anandamide and virodhamine modulate the activity of the candidate cannabinoid receptor GPR55. J Neuroimmune Pharmacol 2012; 7: 856-65.
5. Henstridge CM, Balenga NA, Kargl J, Andradas C, Brown AJ, Irving A, Sanchez C, Waldhoer M. Minireview: recent developments in the physiology and pathology of the lysophosphatidylinositol-sensitive receptor GPR55. Mol Endocrinol 2011; 25: 1835-48.
6. Schicho R, Bashashati M, Bawa M, McHugh D, Saur D, Hu HM, Zimmer A, Lutz B et al. The atypical cannabinoid O-1602 protects against experimental colitis and inhibits neutrophil recruitment. Inflamm Bowel Dis 2011; 17: 1651-64.
7. Li K, Fichna J, Schicho R, Saur D, Bashashati M, Mackie K, Li Y, Zimmer A et al. A role for O-1602 and G protein-coupled receptor GPR55 in the control of colonic motility in mice. Neuropharmacology 2013; 71: 255-63.
8. Lin XH, Yuece B, Li YY, Feng YJ, Feng JY, Yu LY, Li K, Li YN et al. A novel CB receptor GPR55 and its ligands are involved in regulation of gut movement in rodents. Neurogastroenterol Motil 2011; 23: 862-e342.
9. Chiurchiù V, Lanuti M, De Bardi M, Battistini L, Maccarrone M. The differential characterization of GPR55 receptor in human peripheral blood reveals a distinctive expression in monocytes and NK cells and a proinflammatory role in these innate cells. Int Immunol 2015; 27: 153-60.
10. Lauckner JE, Jensen JB, Chen HY, Lu HC, Hille B, Mackie K. GPR55 is a cannabinoid receptor that increases intracellular calcium and inhibits M current. Proc Natl Acad Sci U S A 2008; 105: 2699-704.
11. 2+ signaling and NFAT activation. FASEB J 2009; 23: 183-93.
12. Henstridge CM, Balenga NA, Schröder R, Kargl JK, Platzer W, Martini L, Arthur S, Penman J et al. GPR55 ligands promote receptor coupling to multiple signalling pathways. Br J Pharmacol 2010; 160: 604-14.
13. Kargl J, Brown AJ, Andersen L, Dorn G, Schicho R, Waldhoer M, Heinemann A. A selective antagonist reveals a potential role of G protein-coupled receptor 55 in platelet and endothelial cell function. J Pharmacol Exp Ther 2013; 346: 54-66.
14. Balenga NA, Martínez-Pinilla E, Kargl J, Schröder R, Peinhaupt M, Platzer W, Bálint Z, Zamarbide M et al. Heteromerization of GPR55 and cannabinoid CB(2) receptors modulates signalling. Br J Pharmacol 2014; 171: 5387-406.
15. Kargl J, Balenga N, Parzmair GP, Brown AJ, Heinemann A, Waldhoer M. The cannabinoid receptor CB1 modulates the signaling properties of the lysophosphatidylinositol receptor GPR55. J Biol Chem 2012; 287: 44234-48.
16. Moreno E, Andradas C, Medrano M, Caffarel MM, Pérez-Gómez E, Blasco-Benito S, Gómez-Cañas M, Pazos MR et al. Targeting CB2-GPR55 receptor heteromers modulates cancer cell signaling. J Biol Chem 2014; 289: 21960-72.
17. Izzo AA, Sharkey KA. Cannabinoids and the gut: new developments and emerging concepts. Pharmacol Ther 2010; 126: 21-38.
18. Ross GR, Lichtman A, Dewey WL, Akbarali HI. Evidence for the putative cannabinoid receptor (GPR55)-mediated inhibitory effects on intestinal contractility in mice. Pharmacology 2012; 90: 55-65.
19. Schicho R, Storr M. A potential role for GPR55 in gastrointestinal functions. Curr Opin Pharmacol 2012; 12: 653-8.
20. Staton PC, Hatcher JP, Walker DJ, Morrison AD, Shapland EM, Hughes JP, Chong E, Mander PK et al. The putative cannabinoid receptor GPR55 plays a role in mechanical hyperalgesia associated with inflammatory and neuropathic pain. Pain 2008; 139: 225-36.
21. Andradas C, Caffarel MM, Pérez-Gómez E, Salazar M, Lorente M, Velasco G, Guzmán M, Sánchez C. The orphan G protein-coupled receptor GPR55 promotes cancer cell proliferation via ERK. Oncogene 2011; 30: 245-52.
22. Borrelli F, Romano B, Petrosino S, Pagano E, Capasso R, Coppola D, Battista G, Orlando P et al. Palmitoylethanolamide, a naturally-occurring lipid, is an orally effective intestinal anti-inflammatory agent. Br J Pharmacol 2014; 172: 142-58.
23. Kotsikorou E, Sharir H, Shore DM, Hurst DP, Lynch DL, Madrigal KE, Heynen-Genel S, Milan LB et al. Identification of the GPR55 antagonist binding site using a novel set of high-potency GPR55 selective ligands. Biochemistry 2013; 52: 9456-69.
24. Alex P, Zachos NC, Nguyen T, Gonzales L, Chen TE, Conklin LS, Centola M, Li X. Distinct cytokine patterns identified from multiplex profiles of murine DSS and TNBS-induced colitis. Inflamm Bowel Dis 2009; 15: 341-52.
25. Kimball ES, Wallace NH, Schneider CR, D'Andrea MR, Hornby PJ. Vanilloid receptor 1 antagonists attenuate disease severity in dextran sulphate sodium-induced colitis in mice. Neurogastroenterol Motil 2004; 16: 811-8.
26. Schicho R, Storr M. Topical and systemic cannabidiol improves trinitrobenzene sulfonic acid colitis in mice. Pharmacology 2012; 89: 149-55.
27. Sturm EM, Radnai B, Jandl K, Stančić A, Parzmair GP, Högenauer C, Kump P, Wenzl H et al. Opposing roles of prostaglandin D2 receptors in ulcerative colitis. J Immunol 2014; 193: 827-39.
28. Aksamit RR, Falk W, Leonard EJ. Chemotaxis by mouse macrophage cell lines. J Immunol 1981; 126: 2194-9.
29. Vaddi K, Newton RC. Regulation of monocyte integrin expression by beta-family chemokines. J Immunol 1994; 153: 4721-32.
30. Balenga NA, Aflaki E, Kargl J, Platzer W, Schröder R, Blättermann S, Kostenis E, Brown AJ et al. GPR55 regulates cannabinoid 2 receptor-mediated responses in human neutrophils. Cell Res 2011; 21: 1452-69.
31. Farzi A, Reichmann F, Meinitzer A, Mayerhofer R, Jain P, Hassan AM, Fröhlich EE, Wagner K et al. Synergistic effects of NOD1 or NOD2 and TLR4 activation on mouse sickness behavior in relation to immune and brain activity markers. Brain Behav Immun 2015; 44: 106-20.
32. Mudter J, Weigmann B, Bartsch B, Kiesslich R, Strand D, Galle PR, Lehr HA, Schmidt J et al. Activation pattern of signal transducers and activators of transcription (STAT) factors in inflammatory bowel diseases. Am J Gastroenterol 2005; 100: 64-72.
33. Wu CS, Chen H, Sun H, Zhu J, Jew CP, Wager-Miller J, Straiker A, Spencer C et al. GPR55, a G-protein coupled receptor for lysophosphatidylinositol, plays a role in motor coordination. PLoS ONE 2013; 8: e60314.
34. Naftali T, Bar-Lev Schleider L, Dotan I, Lansky EP, Sklerovsky Benjaminov F, Konikoff FM. Cannabis induces a clinical response in patients with Crohn's disease: a prospective placebo-controlled study. Clin Gastroenterol Hepatol 2013; 11: 1276-80.e1.
35. Massa F, Marsicano G, Hermann H, Cannich A, Monory K, Cravatt BF, Ferri GL, Sibaev A et al. The endogenous cannabinoid system protects against colonic inflammation. J Clin Invest 2004; 113: 1202-9.
36. (-/-) mice by attenuating the activation of T cells and promoting their apoptosis. Toxicol Appl Pharmacol 2012; 258: 256-67.
37. Storr MA, Keenan CM, Emmerdinger D, Zhang H, Yüce B, Sibaev A, Massa F, Buckley NE et al. Targeting endocannabinoid degradation protects against experimental colitis in mice: involvement of CB1 and CB2 receptors. J Mol Med (Berl) 2008; 86: 925-36.
38. Paiotti AP, Artigiani Neto R, Forones NM, Oshima CT, Miszputen SJ, Franco M. Immunoexpression of cyclooxygenase-1 and -2 in ulcerative colitis. Braz J Med Biol Res 2007; 40: 911-8.
39. Hokari R, Kurihara C, Nagata N, Aritake K, Okada Y, Watanabe C, Komoto S, Nakamura M et al. Increased expression of lipocalin-type-prostaglandin D synthase in ulcerative colitis and exacerbating role in murine colitis. Am J Physiol Gastrointest Liver Physiol 2011; 300: G401-8.
40. Wang D, Dubois RN. The role of COX-2 in intestinal inflammation and colorectal cancer. Oncogene 2010; 29: 781-8.
41. Martín AR, Villegas I, Alarcón de la Lastra C. The COX-2 inhibitor, rofecoxib, ameliorates dextran sulphate sodium induced colitis in mice. Inflamm Res 2005; 54: 145-51.
42. Martín AR, Villegas I, La Casa C, Alarcón de la Lastra C. The cyclo-oxygenase-2 inhibitor, rofecoxib, attenuates mucosal damage due to colitis induced by trinitrobenzene sulphonic acid in rats. Eur J Pharmacol 2003; 481: 281-91.
43. Roberts PJ, Morgan K, Miller R, Hunter JO, Middleton SJ. Neuronal COX-2 expression in human myenteric plexus in active inflammatory bowel disease. Gut 2001; 48: 468-72.
44. Singh VP, Patil CS, Jain NK, Kulkarni SK. Aggravation of inflammatory bowel disease by cyclooxygenase-2 inhibitors in rats. Pharmacology 2004; 72: 77-84.
45. Milatovic D, Montine TJ, Aschner M. Prostanoid signaling: dual role for prostaglandin E2 in neurotoxicity. Neurotoxicology 2011; 32: 312-9.
46. Algieri F, Rodriguez-Nogales A, Garrido-Mesa N, Zorrilla P, Burkard N, Pischel I, Sievers H, Benedek B et al. Intestinal anti-inflammatory activity of the Serpylli herba extract in experimental models of rodent colitis. J Crohns Colitis 2014; 8: 775-88.
47. Li L, Wang L, Wu Z, Yao L, Wu Y, Huang L, Liu K, Zhou X et al. Anthocyanin-rich fractions from red raspberries attenuate inflammation in both RAW264.7 macrophages and a mouse model of colitis. Sci Rep 2014; 4: 6234.
48. Forbes E, Murase T, Yang M, Matthaei KI, Lee JJ, Foster PS, Hogan SP. Immunopathogenesis of experimental ulcerative colitis is mediated by eosinophil peroxidase. J Immunol 2004; 172: 5664-75.
49. Kitajima S, Takuma S, Morimoto M. Changes in colonic mucosal permeability in mouse colitis induced with dextran sulfate sodium. Exp Anim 1999; 48: 137-43.
50. Stevceva L, Pavli P, Husband AJ, Doe WF. The inflammatory infiltrate in theacute stage of the dextran sulphate sodium induced colitis: B cell response differs depending on the percentage of DSS used to induce it. BMC Clin Pathol 2001; 1: 3.
51. Scheiffele F, Fuss IJ. Induction of TNBS colitis in mice. Curr Protoc Immunol 2002; Chapter 15: Unit 15.19.
52. Hruz P, Dann SM, Eckmann L. STAT3 and its activators in intestinal defense and mucosal homeostasis. Curr Opin Gastroenterol 2010; 26: 109-15.
53. + Th with a minimum effect on that of Treg in the steady state. Int Immunol 2007; 19: 695-702.
54. Grivennikov S, Karin E, Terzic J, Mucida D, Yu GY, Vallabhapurapu S, Schneller J, Rose-John S et al. IL-6 and Stat3 are required for survival of intestinal epithelial cells and development of colitis-associated cancer. Cancer Cell 2009; 15: 103-13.
55. Rogler G, Andus T, Aschenbrenner E, Vogl D, Falk W, Schölmerich J, Gross V. Alterations of the phenotype of colonic macrophages in inflammatory bowel disease. Eur J Gastroenterol Hepatol 1997; 9: 893-9.
56. Camoglio L, Te Velde AA, Tigges AJ, Das PK, Van Deventer SJ. Altered expression of interferon-gamma and interleukin-4 in inflammatory bowel disease. Inflamm Bowel Dis 1998; 4: 285-90.
57. Hans W, Schölmerich J, Gross V, Falk W. Interleukin-12 induced interferon-gamma increases inflammation in acute dextran sulfate sodium induced colitis in mice. Eur Cytokine Netw 2000; 11: 67-74.